Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CORZIDE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.
250 mg orally twice daily
Nadolol: 14-24 hours (prolonged in renal impairment up to 45 hours); bendroflumethiazide: 8-9 hours (may be prolonged in renal dysfunction).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Nadolol: not extensively metabolized, excreted unchanged in urine. Bendroflumethiazide: minimally metabolized, excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Nadolol: ~73% excreted unchanged in urine via glomerular filtration; bendroflumethiazide: ~30% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Nadolol: <30% bound to albumin; bendroflumethiazide: ~94% bound to albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Nadolol: 1.9-2.5 L/kg (low, consistent with hydrophilic nature); bendroflumethiazide: not well characterized but estimated ~0.5-1 L/kg (small Vd due to high protein binding).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Nadolol: ~30-40% (variable, first-pass metabolism minimal); bendroflumethiazide: bioavailability ~65% (oral).
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: administer every 24 hours; GFR 10-29 m L/min: administer every 24-36 hours; GFR <10 m L/min: administer every 48 hours.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class B or C: use with caution; consider dose reduction or increased monitoring due to reduced clearance.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lower dose (e.g., 1 tablet containing nadolol 20 mg and bendroflumethiazide 2.5 mg) and titrate slowly; monitor renal function and electrolytes.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Bronchospasm in patients with asthma/COPD,Heart failure exacerbation,Peripheral vascular disease worsening,Abrupt withdrawal may cause angina or MI,Masking of hypoglycemia in diabetics,Electrolyte disturbances (hypokalemia, hyponatremia),Increased BUN and serum creatinine,Orthostatic hypotension,Systemic lupus erythematosus exacerbation
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Uncompensated heart failure,Anuria,Hypersensitivity to thiazides or sulfonamides
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid potassium-rich foods (bananas, oranges, spinach, potatoes) in excess unless directed by a physician, as thiazides may cause hypokalemia, but monitoring is needed. Alcohol may potentiate hypotensive effects. Grapefruit juice may increase nadolol levels; avoid concurrent intake.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumethiazide; β-blocker use may increase risk of intrauterine growth restriction. Second trimester: Continued risk of placental insufficiency. Third trimester: Neonatal bradycardia, hypoglycemia, hypotension, and respiratory depression due to nadolol; electrolyte disturbances and volume depletion from bendroflumethiazide.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Nadolol is excreted into breast milk with a relative infant dose of approximately 2-5% of maternal weight-adjusted dose; M/P ratio not well defined. Bendroflumethiazide also appears in breast milk. Consider risk of infant bradycardia, hypotension, and electrolyte disturbances. Avoid use or monitor infant for adverse effects.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established dose adjustment guidelines. Consider reducing nadolol dose due to increased plasma volume and clearance in pregnancy. Bendroflumethiazide typically avoided in pregnancy; if used, monitor for volume depletion and electrolyte imbalance, and consider dose reduction. Clinical judgment required.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Corzide (bendroflumethiazide/nadolol) combines a thiazide diuretic and a non-selective beta-blocker. Monitor for bradycardia, hypotension, hypokalemia, and hyperglycemia. Avoid abrupt withdrawal due to beta-blocker rebound. Use cautiously in asthma, COPD, diabetes, and peripheral vascular disease. Dosage adjustments needed in renal impairment.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this medication suddenly; abrupt cessation can cause chest pain or heart attack.,Avoid alcohol, which can increase dizziness and drowsiness.,Report symptoms of low potassium (muscle cramps, weakness) or slow heart rate (dizziness, fainting).,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Use sunscreen and protective clothing as this medication may increase sensitivity to sunlight.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CORZIDE vs ALDOCLOR-250, answered by our medical review team.
CORZIDE is a Antihypertensive combination that works by Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CORZIDE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CORZIDE is: Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CORZIDE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CORZIDE is classified as Category C. CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumeth. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.